Zoetis Inc. (NYSE:ZTS) Shares Acquired by Scientech Research LLC

Scientech Research LLC boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 139.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,773 shares of the company's stock after buying an additional 7,434 shares during the period. Zoetis makes up about 0.6% of Scientech Research LLC's portfolio, making the stock its 6th largest position. Scientech Research LLC's holdings in Zoetis were worth $2,081,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Select Equity Group L.P. grew its position in Zoetis by 130.6% during the fourth quarter. Select Equity Group L.P. now owns 189,703 shares of the company's stock valued at $30,908,000 after buying an additional 107,455 shares during the period. Sender Co & Partners Inc. bought a new position in shares of Zoetis in the fourth quarter valued at approximately $1,385,000. Snowden Capital Advisors LLC grew its holdings in shares of Zoetis by 9.9% during the fourth quarter. Snowden Capital Advisors LLC now owns 32,287 shares of the company's stock worth $5,260,000 after purchasing an additional 2,921 shares in the last quarter. Sherbrooke Park Advisers LLC purchased a new position in shares of Zoetis during the fourth quarter worth about $868,000. Finally, Royal Bank of Canada grew its holdings in shares of Zoetis by 11.8% during the fourth quarter. Royal Bank of Canada now owns 3,437,895 shares of the company's stock worth $560,137,000 after purchasing an additional 363,843 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now owns 15,781 shares in the company, valued at approximately $2,682,770. This represents a 2.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now owns 11,245 shares in the company, valued at $1,868,244.30. The trade was a 9.71% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.18% of the company's stock.

Wall Street Analysts Forecast Growth

ZTS has been the topic of several research reports. Barclays lifted their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research note on Friday, February 14th. Piper Sandler lifted their price target on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a report on Monday, May 12th. Morgan Stanley decreased their price objective on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a report on Friday, February 14th. StockNews.com upgraded Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Finally, UBS Group dropped their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $212.75.

Zoetis Stock Performance

Shares of NYSE ZTS traded down $0.31 during midday trading on Tuesday, hitting $163.63. 1,780,660 shares of the company's stock traded hands, compared to its average volume of 2,512,361. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The stock has a market capitalization of $72.85 billion, a price-to-earnings ratio of 29.91, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The firm has a fifty day moving average of $156.51 and a 200 day moving average of $165.09.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.22 billion for the quarter, compared to analysts' expectations of $2.20 billion. During the same period in the previous year, the firm earned $1.38 EPS. The business's quarterly revenue was up 1.4% on a year-over-year basis. On average, analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.